Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis
Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates
Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021
Kezar Life Sciences Announces Formation of Clinical Advisory Committee
